Workflow
SIRIO(300791)
icon
Search documents
仙乐健康:关于公司2024年度申请银行综合授信额度的公告
2024-04-21 08:06
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司(以下简称"公司") 于 2024 年 4 月 18 日召 开了第三届董事会第三十一次会议,审议通过了《关于公司 2024 年度申请银行 综合授信额度的议案》,本议案尚需提交公司股东大会审议。现将具体情况公告 如下: 仙乐健康科技股份有限公司 关于公司 2024 年度申请银行综合授信额度的公告 一、基本情况 为预备公司及其全资子公司、控股子公司经营可能出现的资金需求,公司 及其全资子公司、控股子公司拟向各合作银行申请综合授信额度总计不超过人 民币 20 亿元,公司及其全资子公司、控股子公司拟以其各自的自有土地、房 产、设备、资金为其获得授信额度提供担保。 | 证券代码:300791 | 证券简称:仙乐健康 | 公告编码:2024-026 | | --- | --- | --- | | 证券代码:123113 | 证券简称:仙乐转债 | | 1 仙乐健康科技股份有限公司第三届董事会第三十一次会议决议。 特此公告。 仙乐健康科技股份有限公司 董事会 二〇二四年四月二十二日 上述授信最终以相关各 ...
仙乐健康:监事会决议公告
2024-04-21 08:06
| 证券代码:300791 | 证券简称:仙乐健康 | 公告编码:2024-020 | | --- | --- | --- | | 证券代码:123113 | 证券简称:仙乐转债 | | 仙乐健康科技股份有限公司(以下简称"公司")第三届监事会第二十六次 会议于 2024 年 4 月 18 日(星期四)在汕头市龙湖区泰山路 83 号公司会议室以 现场及通讯表决相结合的方式召开。会议通知和增加议案的通知分别于 2024 年 4 月 7 日和 2024 年 4 月 16 日以电子邮件、微信信息等方式送达给全体监事,并 取得全体监事对新增议案列入本次会议议程的同意和认可。本次会议应参加监事 3 人,实际参加监事 3 人。本次会议的召集、召开符合《中华人民共和国公司法》 (以下简称"《公司法》")、《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》、《仙乐健康科技股份有限公司章程》(以下简称"《公 司章程》")和《仙乐健康科技股份有限公司监事会议事规则》的有关规定,会议 合法有效。 二、监事会会议审议情况 经与会监事认真审议,本次会议以回收表决票的表决方式逐项表决通过了以 下决议: 第三届监 ...
仙乐健康:关于召开2023年年度股东大会的通知
2024-04-21 08:06
| 证券代码:300791 | 证券简称:仙乐健康 | 公告编码:2024-033 | | --- | --- | --- | | 证券代码:123113 | 证券简称:仙乐转债 | | 仙乐健康科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司(以下简称"公司"、"本公司")定于 2024 年 5 月 28 日(星期二)召开 2023 年年度股东大会,现将会议有关事项通知如下: 一、本次股东大会召开的基本情况 1、股东大会届次:2023 年年度股东大会。 2、会议召集人:公司第三届董事会。 3、会议召开的合法性、合规性情况:经公司第三届董事会第三十一次会议 审议并通过了《关于提请召开 2023 年年度股东大会的议案》。召集程序符合有关 法律、行政法规、部门规章、规范性文件和公司章程的规定。 4、会议召开日期与时间: (1)现场会议召开时间:2024 年 5 月 28 日(星期二)14:30; (1)截至 2024 年 5 月 21 日下午深圳证券交易所收市时,在中国证券登记 结 ...
仙乐健康(300791) - 2024 Q1 - 季度财报
2024-04-21 08:04
Financial Performance - The company's revenue for Q1 2024 reached ¥951,504,195.36, representing a 35.51% increase compared to ¥702,158,705.58 in the same period last year[4] - Net profit attributable to shareholders was ¥63,029,722.56, a significant increase of 114.39% from ¥29,399,867.21 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥64,930,448.59, up 155.07% from ¥25,455,628.46 in the previous year[4] - The basic earnings per share increased to ¥0.3472, reflecting a growth of 113.14% compared to ¥0.1629 in the same period last year[4] - The net profit for Q1 2024 was CNY 53,871,136.53, a significant increase from CNY 18,758,317.18 in Q1 2023, representing a growth of approximately 187.5%[27] - The operating profit for Q1 2024 was CNY 72,914,248.06, up from CNY 24,965,230.25 in Q1 2023, reflecting a growth of approximately 192.3%[27] - The company reported a total comprehensive income of CNY 27,178,195.12 for Q1 2024, compared to a loss of CNY 110,875,780.68 in Q1 2023[27] Cash Flow and Expenses - The company reported a net cash flow from operating activities of -¥72,301,258.02, a decline of 290.87% from ¥37,879,957.19 in the previous year, primarily due to increased procurement expenses[13] - The company's cash and cash equivalents decreased to RMB 413,703,447.28 from RMB 534,486,633.88 at the beginning of the period, a decline of 22.6%[24] - The cash flow from operating activities showed a net outflow of CNY 72,301,258.02, contrasting with a net inflow of CNY 37,879,957.19 in the same period last year[30] - The company incurred a total investment cash outflow of CNY 180,355,134.16 in Q1 2024, compared to CNY 728,378,578.08 in the previous year[30] - The net cash flow from financing activities was CNY 28,352,482.68, a recovery from a net outflow of CNY 261,283,175.80 in Q1 2023[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,127,433,664.78, a slight decrease of 1.31% from ¥5,195,727,810.16 at the end of the previous year[4] - The total liabilities decreased to RMB 2,549,367,451.40 from RMB 2,629,559,140.26, reflecting a reduction of 3.0%[25] - Accounts receivable increased to RMB 623,889,293.07 from RMB 612,751,607.59, showing a slight increase of 1.9%[24] - Inventory rose to RMB 500,437,189.57 from RMB 481,058,631.43, marking an increase of 4.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,251[15] - Guangdong Guanghui Investment Co., Ltd. holds 42.83% of the shares, amounting to 77,760,000 shares[15] - Lin Peiqing and Chen Qiong, as actual controllers, hold a combined total of 16,588,800 shares, representing 9.14% of the company's equity[16] - The top ten shareholders do not participate in margin trading or securities lending[17] - The total number of restricted shares at the end of the period is 31,605,473, with 10,851 shares released during the period[19] - The company has no preferred shareholders or changes in preferred shareholder structure[17] - The company maintains a stable shareholder structure with no significant changes reported[17] - The report indicates that Lin Peiqing holds shares as a trustee, with economic benefits directed to the beneficiaries of the trust[16] Research and Development - Research and development expenses rose to ¥30,794,385.11, marking a 36.99% increase from ¥22,478,475.33 in the previous year, indicating a focus on innovation[11] Marketing and Sales - Sales expenses increased by 39.75% to ¥73,086,246.12, attributed to enhanced marketing activities and sales team upgrades[11] Taxation - The company experienced a 150.64% increase in income tax expenses, amounting to ¥15,453,196.98, driven by business growth[11] - The company reported a tax expense of CNY 15,453,196.98 for Q1 2024, compared to CNY 6,165,404.20 in the same period last year, indicating an increase of approximately 150.0%[27] Investments and Joint Ventures - The company established a joint investment fund with Shanghai Hongzhang, targeting a total subscription amount of up to RMB 204 million, with an initial subscription of RMB 130 million[20] - The company completed its share repurchase plan, buying back 1,285,600 shares, representing 0.71% of the total share capital, for a total amount of RMB 39,899,697.35[21] Market and Product Development - The company has not disclosed any new product or technology developments in the current report[19] - There are no indications of market expansion or mergers and acquisitions in the current reporting period[19]
仙乐健康:董事会决议公告
2024-04-21 08:04
| 证券代码:300791 | 证券简称:仙乐健康 | 公告编码:2024-019 | | --- | --- | --- | | 证券代码:123113 | 证券简称:仙乐转债 | | 仙乐健康科技股份有限公司 第三届董事会第三十一次会议决议公告 1、审议通过了《2023 年年度报告及摘要》 经审议,董事会认为:公司编制《2023 年年度报告》及《2023 年年度报告 摘要》的程序符合法律、法规和中国证监会的规定;报告内容真实、准确、完整 地反映了公司实际情况,不存在任何虚假记载、误导性陈述或者重大遗漏。 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 仙乐健康科技股份有限公司(以下简称"公司")第三届董事会第三十一次 会议于 2024 年 4 月 18 日(星期四)在上海市青浦区公司研发中心会议室以现场 及通讯表决相结合的方式召开。会议通知和增加议案的通知分别于 2024 年 4 月 7 日和 2024 年 4 月 16 日以电子邮件、微信信息等方式送达给全体董事,并取得 全体董事对本次会议如期举行的同意和认可。本次会议应参加 ...
仙乐健康:招商证券股份有限公司关于仙乐健康科技股份有限公司使用闲置募集资金进行现金管理的核查意见
2024-04-21 08:04
招商证券股份有限公司 关于仙乐健康科技股份有限公司 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司(以下简称"招商证券"或"保荐机构")作为仙乐 健康科技股份有限公司(以下简称"仙乐健康"或"公司")向不特定对象发行 可转换公司债券的保荐机构及持续督导机构,根据《证券发行上市保荐业务管理 办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 2 号—创业板上市公司规范运作》及《上市公司监管指引第 2 号— 上市公司募集资金管理和使用的监管要求》等有关规定,对仙乐健康拟使用闲置 募集资金进行现金管理的事项进行了审慎核查,核查情况及核查意见如下: 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意仙乐健康科技股份有限公司向不特定 对象发行可转换公司债券注册的批复》(证监许可[2021]927 号)同意注册,公司 向不特定对象发行可转换公司债券数量 10,248,929 张,募集资金总额为 102,489.29 万元,扣除发行费用 1,148.43 万元,实际募集资金净额为 101,340.86 万元。上述募集资金到位情况已经华兴会计师事务所(特殊普通合伙)审 ...
仙乐健康:2023年监事会工作报告
2024-04-21 08:04
仙乐健康科技股份有限公司 2023 年度监事会工作报告 2023 年,仙乐健康科技股份有限公司(以下简称"公司")监事会严格按照 《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》 (以下简称"《证券法》")、《仙乐健康科技股份有限公司章程》(以下简称"《公 司章程》")、《仙乐健康科技股份有限公司监事会议事规则》(以下简称"《监事会 议事规则》")等有关法律法规和公司规章制度的要求,在工作中勤勉尽责,积极 列席董事会并出席股东大会,切实维护公司利益和广大股东权益,认真履行了监 事会的知情监督检查职能。现将监事会 2023 年度主要工作情况报告如下: 一、2023 年监事会日常工作情况 报告期内,公司监事会除列席公司董事会及出席股东大会会议外,共召开了 11 次监事会会议。内容如下: 监事会对 2023 年度公司的财务状况、财务管理等进行了有效的监督、检查 和审核,认为: 公司财务制度健全、内控制度完善、财务运作规范、财务状况良好,财务报 告真实、客观地反映了公司 2023 年度的财务状况和经营成果。 (三)关联交易情况 监事会对公司关联交易进行核查后认为: | 序号 | 届次 | ...
仙乐健康:关于公司2024年度使用闲置自有资金进行现金管理额度的公告
2024-04-21 08:04
| 证券代码:300791 | 证券简称:仙乐健康 | 公告编码:2024-029 | | --- | --- | --- | | 证券代码:123113 | 证券简称:仙乐转债 | | 仙乐健康科技股份有限公司 关于公司 2024 年度使用闲置自有资金进行 现金管理额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司(含子公司,以下简称"公司")于 2024 年 4 月 18 日召开第三届董事会第三十一次会议和第三届监事会第二十六次会议,分别 审议通过了《关于公司 2024 年度使用闲置自有资金进行现金管理额度的议案》, 同意使用额度不超过人民币 60,000 万元的闲置自有资金择机购买低风险、高流 通性的短期理财产品,使用期限为 2023 年年度股东大会审议通过之日起至 2024 年年度股东大会召开之日止。在上述额度范围和使用期限内资金可滚动使用。在 该使用期限内,公司(含子公司)使用闲置自有资金购买或投资的单个理财产品 的投资期限不超过 12 个月。在上述额度范围和使用期限内,授权董事长行使该 项投资决策权并由财务负责人负 ...
仙乐健康(300791) - 2023 Q4 - 年度财报
2024-04-21 08:04
Financial Performance - The company reported a revenue increase of 15% year-over-year, reaching approximately 1.2 billion yuan in 2023[12]. - The company has set a revenue guidance of 1.5 billion yuan for 2024, representing a projected growth of 25%[12]. - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a 15% increase compared to the previous year[28]. - The company expects a revenue growth of 20% for the next fiscal year, projecting revenues to reach 1.44 billion RMB[28]. - The company's operating revenue for 2023 reached ¥3,582,022,297.17, representing a 42.87% increase compared to ¥2,507,261,818.80 in 2022[33]. - The net profit attributable to shareholders for 2023 was ¥281,038,527.77, a 32.39% increase from ¥212,285,578.09 in 2022[33]. - The total revenue for 2023 reached ¥3,582,022,297.17, representing a year-on-year increase of 42.87% compared to ¥2,507,261,818.80 in 2022[107]. - The main business revenue amounted to ¥3,568,107,343.10, accounting for 99.61% of total revenue, with a growth of 43.12% year-on-year[107]. User Growth and Market Expansion - User data indicates a growth in active customers by 25%, totaling 3 million users by the end of 2023[12]. - User data showed a growth in active users by 25%, reaching 5 million by the end of 2023[28]. - The company aims to expand its market reach in Europe and North America, targeting a 30% increase in international sales by 2025[12]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[28]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[184]. Research and Development - The company has invested 100 million yuan in R&D for new product development, focusing on innovative health supplements[12]. - Research and development expenses increased by 18%, totaling 150 million RMB, focusing on innovative health solutions[28]. - The company has been actively involved in research and development of new health products to meet the growing demand in the nutrition and health food market[42]. - The company has established a product development team led by PhDs to continuously innovate in formula and dosage form technology[67]. - The company has developed innovative dosage forms such as gel soft capsules and probiotic crystal balls, enhancing product nutritional value through technological breakthroughs[69]. - The company launched several new health food products, including "Tian Can® DHA Algal Oil Soft Capsules" and "An Yi Jia® Cod Liver Oil Soft Capsules," with registration valid until 2028[92][93]. Acquisitions and Strategic Partnerships - The acquisition of Best Formulations in the US is expected to enhance the company's market presence and operational efficiency[12]. - The company completed a strategic acquisition of a competitor for 200 million RMB, enhancing its product portfolio[28]. - The company has acquired Best Formulations in the U.S. and established a cross-border factory in Zhuhai, strengthening global supply capabilities[69]. - The acquisition of 71.41% equity in Best Formulations LLC is aimed at expanding the company's business in the Americas and enhancing global market competitiveness[154]. Financial Management and Investments - The company plans to distribute a cash dividend of 11 yuan per 10 shares, alongside a capital increase of 3 shares for every 10 shares held[12]. - The company has a liquidity fund of 13,851 million CNY, which is fully utilized[146]. - The company invested ¥1,184,579,912.56 during the reporting period, a significant increase of 303.34% compared to the previous year[136]. - The company has committed to several investment projects, including a production base in Anshan with an investment of 69,585 million CNY, which is 84.11% completed[146]. Product Development and Innovation - New product launches contributed to 30% of total revenue, with three major products introduced in Q4 2023[28]. - The company focuses on six key categories: anti-aging, probiotics, beauty health, cardiovascular metabolism, immune enhancement, and sports nutrition, with strategies showing initial success in 2023[66]. - The company is focusing on building a flexible manufacturing system and an excellent supply chain to reduce costs and improve efficiency[103]. - The company is focusing on innovative product development, including plant-based soft capsules and probiotic products, to meet diverse health needs across different age groups[82]. Market Trends and Consumer Behavior - The global retail scale of the nutrition and health food market exceeded $187 billion in 2023, with a compound annual growth rate (CAGR) of 6.5% over the past three years, expected to reach $223 billion by 2026[46]. - The U.S. nutrition and health food market grew to over $60 billion in 2023, with a year-on-year increase of 5.8%, projected to slow to 4% growth in the future[47]. - The aging population in China, with approximately 300 million people aged over 60, is significantly driving the demand for health products, with a 16% year-on-year increase in per capita healthcare spending[50]. - The nutrition and health food market in South Korea, Australia, and New Zealand exceeded $9.6 billion in 2023, with a year-on-year growth of over 5%[58]. Governance and Compliance - The company maintains a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring coordination and checks and balances among decision-making, supervision, and management[189]. - The board of directors comprises 7 members, including 3 independent directors, meeting legal and regulatory requirements[192]. - The company respects and protects the legitimate rights and interests of stakeholders, promoting balanced interests among shareholders, employees, and society[195]. - The company strictly adheres to legal regulations and its own disclosure management system, ensuring timely and fair information disclosure[198].
仙乐健康:董事会对独董独立性评估的专项意见
2024-04-21 08:04
经核查独立董事胡世明、朱桂龙、高见的任职经历以及其各自签署的相关自 查报告,上述人员未在公司担任除独立董事以外的任何职务,也未在公司主要股 东或其所控制的公司担任任何职务,与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系,因此,公司独立董事符合《上市公司 独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》中对独立董事独立性 的相关要求。 根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等要求,仙乐健康科技股份有限公司(以下简称"公司")董事会就公 司在任独立董事胡世明、朱桂龙、高见的独立性情况进行评估并出具如下专项意 见: 仙乐健康科技股份有限公司董事会 关于独立董事独立性自查情况的专项报告 仙乐健康科技股份有限公司 董事会 二〇二四年四月二十二日 ...